Omicron Pharmaceuticals
Company
Omicron Pharmaceuticals develops one asset, in phase 3 (lycopene in metabolic disease). Mostly supplement acting on Oxidative stress and ROS signalling.
- 1
- Asset
- Furthest stage
- Phase 3
- 1
- Trial
- 0
- Signals
Pipeline
1Antioxidant carotenoid supplement
Phase 3, Supplement, Oxidative stress and ROS signalling, metabolic disease
Full company profiles: pipeline, trials, funding and people.
In the full profile
- Evidence behind the mechanisms2
- Trials3
- Similar companies6